Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript

Moderna, Inc. ( MRNA ) Q2 2026 Earnings Call July 31, 2026 8:00 AM EDT Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Chief Financial Officer Stephen Hoge - President David Berman - Chief Development Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Eliana Merle - Barclays Bank PLC, Research Division Terence Flynn - Morgan Stanley, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Lin Tsai - Jefferies LLC, Research Division Courtney Breen - Bernstein Institutional Services LLC, Research Division Michael Yee - UBS Investment Bank, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Moderna Second Quarter 2026 Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Lavina Talukdar Senior VP & Head of Investor Relations Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's second quarter 2026 financial results and business update. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; Jamey Mock, our Chief Financial Officer; and David Berman, our Chief Development Officer. Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation.